Hospital for Special Surgery United States

Dr Giorgio Perino
Pathologist dealing with rheumatic diseases, osteoarthritis, and inflammatory reaction to implants 

Hospital for special surgery United States

HSS is nationally ranked #1 in orthopedics, and #3 in rheumatology by U.S.News & World Report (2015-16). HSS has been top-ranked for both orthopedics and rheumatology for the 24 consecutive years.

Because an infection can be a devastating outcome for an orthopedic patient, Hospital for Special Surgery takes infection control extremely seriously and is proud of the recognition received for our significantly low infection rates

HSS and a complement of physicians within each specialty area accepts most major insurance plans. Our Insurance Advisory Service can answer questions regarding your insurance coverage.

Dr rupali joshi
research therapist 

Hospital for Special Surgery United States

Rahul Remanan

Humana United States

Paulette Daniel
Consultant, Human Capital 


HYBRIGENICS Hybrigenics is a biopharmaceutical company involved in the discovery and the development of new anticancer drugs. Industry sectors Biotech Therapeutics Area Oncology
Your innovative solution

Hybrigenics is developing inecalcitol, a vitamin D receptor agonist, characterized by enhanced activities against cancer cell proliferation and much reduced toxicity on blood calcium levels as compared to calcitriol, the active form of vitamin D. Therefore, inecalcitol can be given at high daily oral doses which exert cytostatic effects on tumors. 

Which problem are you solving ?

Acute myeloid leukemia (AML) has the worse prognosis of all types of leukemias (<25% 5-year survival). Furthermore, elderly or frail AML patients cannot support standard induction chemotherapy and are eligible only to treatment with either decitabine or azacytidine, two hypo-methylating agents. The goal is to increase overall survival of these desperate patients by adding daily oral inecalcitol to hypo-methylating therapy.

Target market segments

Pharmaceutical products / anticancer agents / hematological malignancies / small chemical drugs /

Key value proposition

Orphan drug status already granted for AML in US and EU / Excellent tolerance in patients / convenient daily oral dosing favoring compliance / Strong proof of principle in animal AML models